AstraZeneca Gains US Asthma Approval for Triple-Combo Breztri
Event summary
- AstraZeneca’s BREZTRI Aerosphere (budesonide/glycopyrrolate/formoterol fumarate) received FDA approval for maintenance treatment of asthma in US patients 12+.
- The approval is based on Phase III KALOS and LOGOS trials demonstrating improved lung function compared to dual-combination ICS/LABA therapies.
- BREZTRI previously gained US approval for COPD in 2020 and has been prescribed to over 6.8 million patients globally as of 2025.
- The therapy combines a corticosteroid, long-acting beta2-agonist (LABA), and long-acting muscarinic antagonist (LAMA) in a single inhaler.
The big picture
AstraZeneca’s approval of Breztri for asthma represents a strategic expansion of a successful COPD therapy into a large, underserved market of 27 million US asthma sufferers. The triple-combination approach addresses the limitations of existing dual therapies, potentially capturing market share from established competitors. This move underscores AstraZeneca’s focus on respiratory disease and its commitment to innovation in the field.
What we're watching
- Market Penetration
- The speed of adoption among asthma patients, particularly those currently uncontrolled on dual therapies, will be a key indicator of Breztri’s commercial success.
- Regulatory Landscape
- Approval in the EU, Japan, and China will be critical for maximizing global revenue potential, and any delays could impact AstraZeneca’s overall respiratory portfolio growth.
- Competitive Response
- Competitors like Symbicort and others will likely respond with marketing campaigns and potentially new product development, intensifying competition in the asthma maintenance market.
Related topics